Development PipelineEnfortumab vedotin

an antibody–drug conjugate being investigated in urothelial carcinoma and other solid tumors

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

EV-302/KEYNOTE-A39: Locally advanced or metastatic urothelial cancer (EV + pembrolizumab vs chemotherapy)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

KEYNOTE-905/EV-303: Cisplatin-ineligible/decline muscle-invasive bladder cancer (perioperative pembrolizumab ± EV + RC + PLND vs RC + PLND alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

KEYNOTE-B15/EV-304: Cisplatin-eligible muscle-invasive bladder cancer (perioperative EV + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-103/KEYNOTE-869: Urothelial cancer (EV alone or with other therapies)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-202: Locally advanced or metastatic solid tumors (EV alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

EV-104: BCG-unresponsive non-muscle-invasive bladder cancer (intravesical EV alone)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of enfortumab vedotin and ongoing clinical trials

View/Download

Detailed information about enfortumab vedotin clinical trials

View in Interactive Pipeline